title: AbbVie considers harms to be commercially confidential information: sign a petition.
authors.affiliation: Nordic Cochrane Centre, Rigshospitalet, Denmark.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Gøtzsche
mesh_terms: D022126:Access to Information / Q000331:legislation & jurisprudence; D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D003219:Confidentiality / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D005062:European Union; D006801:Humans; D011728:Pyridones / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011728:Pyridones; C093844:pirfenidone; D000068879:Adalimumab